Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Diabetes and heart failure in the post-myocardial infarction patient.

Literature DB >> 17129509

Diabetes and heart failure in the post-myocardial infarction patient.

Abstract

Diabetes mellitus, a disease which is increasing in prevalence, is a major risk factor for coronary heart disease. In patients following acute myocardial infarction, the presence of diabetes is a powerful risk factor for the development of heart failure, and this intersection of heart failure and diabetes following myocardial infarction carries substantial risk. The poor prognosis associated with heart failure in diabetic patients following myocardial infarction is likely multifactorial. Aggressive strategies for prevention and treatment of heart failure are crucial to reducing the risk associated with diabetes and heart failure following myocardial infarction. This review summarizes epidemiologic, pathophysiologic, and therapeutic data related to diabetes and heart failure in the post-myocardial infarction setting.

Entities: Disease Species

Mesh：

Year: 2006 PMID： 17129509 DOI： 10.1007/s11897-006-0017-7

Source DB: PubMed Journal: Curr Heart Fail Rep ISSN： 1546-9530

50 in total

1. Clinical characteristics and long-term outcome of patients in whom congestive heart failure develops after thrombolytic therapy for acute myocardial infarction: development of a predictive model.

Authors: C M O'Connor; W R Hathaway; E R Bates; J D Leimberger; K N Sigmon; D J Kereiakes; B S George; J K Samaha; C W Abbottsmith; R J Candela; E J Topol; R M Califf
Journal: Am Heart J Date: 1997-06 Impact factor: 4.749

2. Haptoglobin polymorphism predicts 30-day mortality and heart failure in patients with diabetes and acute myocardial infarction.

Authors: Mahmoud Suleiman; Doron Aronson; Rabea Asleh; Michael R Kapeliovich; Ariel Roguin; Simcha R Meisel; Michael Shochat; Abeer Sulieman; Shimon A Reisner; Walter Markiewicz; Haim Hammerman; Rachel Lotan; Nina S Levy; Andrew P Levy
Journal: Diabetes Date: 2005-09 Impact factor: 9.461

3. Impact of diabetes mellitus on myocardial perfusion after primary angioplasty in patients with acute myocardial infarction.

Authors: Abhiram Prasad; Gregg W Stone; Thomas D Stuckey; Costantino O Costantini; Peter J Zimetbaum; Michael McLaughlin; Roxana Mehran; Eulogio Garcia; James E Tcheng; David A Cox; Cindy L Grines; Alexandra J Lansky; Bernard J Gersh
Journal: J Am Coll Cardiol Date: 2005-02-15 Impact factor: 24.094

4. Insulin resistance and risk of congestive heart failure.

Authors: Erik Ingelsson; Johan Sundström; Johan Arnlöv; Björn Zethelius; Lars Lind
Journal: JAMA Date: 2005-07-20 Impact factor: 56.272

Review 5. Are beta-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials.

Authors: Steven Joseph Haas; Theo Vos; Richard E Gilbert; Henry Krum
Journal: Am Heart J Date: 2003-11 Impact factor: 4.749

6. The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: contribution of both coronary disease and diastolic left ventricular dysfunction to the adverse prognosis. The MILIS Study Group.

Authors: P H Stone; J E Muller; T Hartwell; B J York; J D Rutherford; C B Parker; Z G Turi; H W Strauss; J T Willerson; T Robertson
Journal: J Am Coll Cardiol Date: 1989-07 Impact factor: 24.094

7. Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril.

Authors: M St John Sutton; M A Pfeffer; T Plappert; J L Rouleau; L A Moyé; G R Dagenais; G A Lamas; M Klein; B Sussex; S Goldman
Journal: Circulation Date: 1994-01 Impact factor: 29.690

8. Increased levels of tumour necrosis factor-alpha (TNF-alpha) in patients with Type II diabetes mellitus after myocardial infarction are related to endothelial dysfunction.

Authors: Thomas Nyström; Arne Nygren; Ake Sjöholm
Journal: Clin Sci (Lond) Date: 2006-06 Impact factor: 6.124

9. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.

Authors: Marc A Pfeffer; John J V McMurray; Eric J Velazquez; Jean-Lucien Rouleau; Lars Køber; Aldo P Maggioni; Scott D Solomon; Karl Swedberg; Frans Van de Werf; Harvey White; Jeffrey D Leimberger; Marc Henis; Susan Edwards; Steven Zelenkofske; Mary Ann Sellers; Robert M Califf
Journal: N Engl J Med Date: 2003-11-10 Impact factor: 91.245

10. Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: a double-blind placebo-controlled study.

Authors: Giuseppe M C Rosano; Cristiana Vitale; Barbara Sposato; Giuseppe Mercuro; Massimo Fini
Journal: Cardiovasc Diabetol Date: 2003-11-28 Impact factor: 9.951

7 in total

Diabetes and heart failure in the post-myocardial infarction patient.

1. Clinical characteristics and long-term outcome of patients in whom congestive heart failure develops after thrombolytic therapy for acute myocardial infarction: development of a predictive model.

2. Haptoglobin polymorphism predicts 30-day mortality and heart failure in patients with diabetes and acute myocardial infarction.

3. Impact of diabetes mellitus on myocardial perfusion after primary angioplasty in patients with acute myocardial infarction.

4. Insulin resistance and risk of congestive heart failure.

Review 5. Are beta-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials.

6. The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: contribution of both coronary disease and diastolic left ventricular dysfunction to the adverse prognosis. The MILIS Study Group.

7. Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril.

8. Increased levels of tumour necrosis factor-alpha (TNF-alpha) in patients with Type II diabetes mellitus after myocardial infarction are related to endothelial dysfunction.

9. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.

10. Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: a double-blind placebo-controlled study.

Review 1. Proteinaceous cysteine protease inhibitors.

Review 2. Diabetic cardiomyopathy: bench to bedside.

Review 3. The mitochondria in diabetic heart failure: from pathogenesis to therapeutic promise.

4. Identifying disrupted pathways by tracking altered modules in type 2 DM-related heart failure.

5. MicroRNA dysregulation in diabetic ischemic heart failure patients.

6. Use of secondary prevention pharmacotherapy after first myocardial infarction in patients with diabetes mellitus.

7. Improvements in long standing cardiac pathologies by individualized homeopathic remedies: A case series.